Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 3 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nalpropion Pharmaceuticals LLC has 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 5 distinct examiners, providing a variety of examiner reviews. This distribution means that the company's prosecution outcomes are not overly dependent on the tendencies of any single examiner. The variety of examiners involved may lead to different prosecution timelines and outcomes for the pending applications across the pharmaceutical portfolio.
The portfolio is active across 4 distinct art units. Michael J. Schmitt is the busiest examiner for the company, currently handling 2 pending office actions. This distribution shows that while the workload is spread across multiple examiners and 4 distinct art units, there is some concentration with one examiner. This variety of reviewers requires the company to maintain a flexible prosecution strategy that can adapt to different examiner styles and technical focuses. Practitioners should be prepared for a diverse set of feedback across these multiple pending applications.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §102 only | 1 (17%) |
| §112 only | 1 (17%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHMITT, MICHAEL J | 1 | 56.8% | +20.7% |
| RAO, SAVITHA M | 1 | 60.7% | +30.2% |
| RICCI, CRAIG D | 1 | 53.5% | +52.7% |
| BAEK, BONG-SOOK | 1 | 41.7% | +69.9% |
| IVANOVA, SVETLANA M | 1 | 50.9% | +51.5% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +35.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17717691 | Increasing Drug Bioavailability In Naltrexone Therapy | RICCI, CRAIG D | 34d |
| 18770144 | Methods For Administering Weight Loss Medications | SCHMITT, MICHAEL J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17336546 | Methods For Reducing Binge Or Compulsive Eating | IVANOVA, SVETLANA M | 9d |
| 17346902 | Methods Of Providing Weight Loss Therapy In Patients With Major Depression | BAEK, BONG-SOOK | 28d |
| 17717691 | Increasing Drug Bioavailability In Naltrexone Therapy | RICCI, CRAIG D | 34d |
| 18770144 | Methods For Administering Weight Loss Medications | SCHMITT, MICHAEL J | — |
| 18731965 | Compositions And Methods For Reducing Major Adverse Cardiovascular Events | RAO, SAVITHA M | — |
| 17335646 | Compositions and Methods for Increasing Insulin Sensitivity | PECKHAM, RICHARD GRANT | — |
| Art Unit | Apps |
|---|---|
| 1611 | 2 |
| 1627 | 2 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18770144 | Methods For Administering Weight Loss Medications | SCHMITT, MICHAEL J | — | §101DP | Non-Final OA | — | Pending | Jul 11, 2024 |
| 18731965 | Compositions And Methods For Reducing Major Adverse Cardiovascular Events | RAO, SAVITHA M | 1691 | §102DP | Non-Final OA | — | Pending | Jun 03, 2024 |
| 17717691 | Increasing Drug Bioavailability In Naltrexone Therapy | RICCI, CRAIG D | 1611 | §103§112Other | Final Rejection | 34d | Pending | Apr 11, 2022 |
| 17346902 | Methods Of Providing Weight Loss Therapy In Patients With Major Depression | BAEK, BONG-SOOK | 1611 | §112Other | Final Rejection | 28d | Pending | Jun 14, 2021 |
| 17336546 | Methods For Reducing Binge Or Compulsive Eating | IVANOVA, SVETLANA M | 1627 | §102 | Non-Final OA | 9d | Pending | Jun 02, 2021 |
| 17335646 | Compositions and Methods for Increasing Insulin Sensitivity | PECKHAM, RICHARD GRANT | 1627 | §103§112DPOther | Non-Final OA | — | Pending | Jun 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial